Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00057031|
Recruitment Status : Unknown
Verified February 2005 by Novacea.
Recruitment status was: Active, not recruiting
First Posted : April 1, 2003
Last Update Posted : November 1, 2006
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Primary Completion Date :||No date given|
|Study Completion Date :||March 2004|
Mellibovsky L, Díez A, Pérez-Vila E, Serrano S, Nacher M, Aubía J, Supervía A, Recker RR. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol. 1998 Mar;100(3):516-20.
Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001 Jun 15;91(12):2431-9.